{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:16:19Z","timestamp":1794352579861,"version":"4.9.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474506"],"award-info":[{"award-number":["82474506"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403377"],"award-info":[{"award-number":["82403377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Innovation Project of Shanghai Education Committee","award":["2021-01-07-00-07-E00080"],"award-info":[{"award-number":["2021-01-07-00-07-E00080"]}]},{"DOI":"10.13039\/501100007279","name":"Shanghai Municipal Health Bureau","doi-asserted-by":"publisher","award":["2020CXJQ03"],"award-info":[{"award-number":["2020CXJQ03"]}],"id":[{"id":"10.13039\/501100007279","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0510300"],"award-info":[{"award-number":["2023ZD0510300"]}]},{"DOI":"10.13039\/501100014137","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2025CCS007"],"award-info":[{"award-number":["SHDC2025CCS007"]}],"id":[{"id":"10.13039\/501100014137","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02447-y","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:35:08Z","timestamp":1759408508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hsa_circ_0038737 promotes PARPi resistance in castration-resistant prostate cancer via IGF2BP3-mediated DNPH1 mRNA stabilization"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhongyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qintao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihetaimujiang","family":"Anwaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2447_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ctrv.2013.09.011","volume":"40","author":"A Egan","year":"2014","unstructured":"Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev. 2014;40:426\u201333.","journal-title":"Cancer Treat Rev"},{"key":"2447_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2447_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41419-024-06949-3","volume":"15","author":"S Sarwar","year":"2024","unstructured":"Sarwar S, Morozov VM, Newcomb MA, Yan B, Brant JO, Opavsky R, Guryanova OA, Ishov AM. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer. Cell Death Dis. 2024;15:558.","journal-title":"Cell Death Dis"},{"key":"2447_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"2447_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s44178-024-00118-4","volume":"3","author":"B Dai","year":"2024","unstructured":"Dai B, Wang H, Shi B, Xing J, Zhu S, He Z, et al. CACA guidelines for holistic integrative management of prostate cancer. Holist Integr Oncol. 2024;3:47.","journal-title":"Holist Integr Oncol"},{"key":"2447_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.urolonc.2020.03.022","volume":"38","author":"J Kumar","year":"2020","unstructured":"Kumar J, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, et al. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. Urol Oncol. 2020;38:826\u201334.","journal-title":"Urol Oncol"},{"key":"2447_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"2447_CR8","doi-asserted-by":"crossref","unstructured":"Abida W, Armenia J, Gopalan A, Brennan R, Walsh M, Barron D, Danila D, Rathkopf D, Morris M, Slovin S et al. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precis Oncol 2017, 2017.","DOI":"10.1200\/PO.17.00029"},{"key":"2447_CR9","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21870","author":"C Hage Chehade","year":"2025","unstructured":"Hage Chehade C, Gebrael G, Sayegh N, Ozay ZI, Narang A, Crispino T, et al. A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025. https:\/\/doi.org\/10.3322\/caac.21870.","journal-title":"CA Cancer J Clin"},{"key":"2447_CR10","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1001\/jamaoncol.2024.3074","volume":"10","author":"CH Marshall","year":"2024","unstructured":"Marshall CH, Teply BA, Lu J, Oliveira L, Wang H, Mao SS, et al. Olaparib without androgen deprivation for high-risk biochemically recurrent prostate cancer following prostatectomy: a nonrandomized controlled trial. JAMA Oncol. 2024;10:1400\u20138.","journal-title":"JAMA Oncol"},{"key":"2447_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.","journal-title":"Mol Cancer"},{"key":"2447_CR12","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","volume":"42","author":"G Seed","year":"2024","unstructured":"Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, Tyler M, Figueiredo I, Pereira R, Baker C, et al. Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. Cancer Cell. 2024;42:2113\u2013e21232114.","journal-title":"Cancer Cell"},{"key":"2447_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","volume":"14","author":"D Teyssonneau","year":"2021","unstructured":"Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Prostate cancer and PARP inhibitors: progress and challenges. J Hematol Oncol. 2021;14:51.","journal-title":"J Hematol Oncol"},{"key":"2447_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100744","volume":"55","author":"M Chiappa","year":"2021","unstructured":"Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer. Drug Resist Updat. 2021;55:100744.","journal-title":"Drug Resist Updat"},{"key":"2447_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100937","volume":"67","author":"X Guo","year":"2023","unstructured":"Guo X, Gao C, Yang DH, Li S. Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance. Drug Resist Updat. 2023;67:100937.","journal-title":"Drug Resist Updat"},{"key":"2447_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01766-2","volume":"22","author":"ZH Zhang","year":"2023","unstructured":"Zhang ZH, Wang Y, Zhang Y, Zheng SF, Feng T, Tian X, et al. The function and mechanisms of action of circular RNAs in urologic cancer. Mol Cancer. 2023;22:61.","journal-title":"Mol Cancer"},{"key":"2447_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12943-020-01231-4","volume":"19","author":"S Ma","year":"2020","unstructured":"Ma S, Kong S, Wang F, Ju S. Circrnas: biogenesis, functions, and role in drug-resistant tumours. Mol Cancer. 2020;19:119.","journal-title":"Mol Cancer"},{"key":"2447_CR18","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","volume":"24","author":"VM Conn","year":"2024","unstructured":"Conn VM, Chinnaiyan AM, Conn SJ. Circular RNA in cancer. Nat Rev Cancer. 2024;24:597\u2013613.","journal-title":"Nat Rev Cancer"},{"key":"2447_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00628-z","volume":"29","author":"X Cheng","year":"2024","unstructured":"Cheng X, Yang H, Chen Y, Zeng Z, Liu Y, Zhou X, et al. METTL3-mediated m(6)A modification of circGLIS3 promotes prostate cancer progression and represents a potential target for ARSI therapy. Cell Mol Biol Lett. 2024;29:109.","journal-title":"Cell Mol Biol Lett"},{"key":"2447_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13046-022-02404-3","volume":"41","author":"L Chen","year":"2022","unstructured":"Chen L, Song Y, Hou T, Li X, Cheng L, Li Y, Xing Y. Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. J Exp Clin Cancer Res. 2022;41:194.","journal-title":"J Exp Clin Cancer Res"},{"key":"2447_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20:285\u201395.","journal-title":"Nat Cell Biol"},{"key":"2447_CR22","doi-asserted-by":"publisher","first-page":"6809","DOI":"10.1038\/s41467-023-42544-4","volume":"14","author":"NJ Rzechorzek","year":"2023","unstructured":"Rzechorzek NJ, Kunzelmann S, Purkiss AG, Silva Dos Santos M, MacRae JI, Taylor IA, Fugger K, West SC. Mechanism of substrate hydrolysis by the human nucleotide pool sanitiser DNPH1. Nat Commun. 2023;14:6809.","journal-title":"Nat Commun"},{"key":"2447_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1126\/science.abb4542","volume":"372","author":"K Fugger","year":"2021","unstructured":"Fugger K, Bajrami I, Silva Dos Santos M, Young SJ, Kunzelmann S, Kelly G, Hewitt G, Patel H, Goldstone R, Carell T, et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors. Science. 2021;372:156\u201365.","journal-title":"Science"},{"key":"2447_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cell.2014.09.001","volume":"159","author":"XO Zhang","year":"2014","unstructured":"Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell. 2014;159:134\u201347.","journal-title":"Cell"},{"key":"2447_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41580-020-0243-y","volume":"21","author":"LL Chen","year":"2020","unstructured":"Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat Rev Mol Cell Biol. 2020;21:475\u201390.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2447_CR26","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.cell.2015.02.014","volume":"160","author":"SJ Conn","year":"2015","unstructured":"Conn SJ, Pillman KA, Toubia J, Conn VM, Salmanidis M, Phillips CA, Roslan S, Schreiber AW, Gregory PA, Goodall GJ. The RNA binding protein quaking regulates formation of circrnas. Cell. 2015;160:1125\u201334.","journal-title":"Cell"},{"key":"2447_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004029","author":"H Li","year":"2022","unstructured":"Li H, Luo F, Jiang X, Zhang W, Xiang T, Pan Q, et al. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004029.","journal-title":"J Immunother Cancer"},{"key":"2447_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-025-02254-5","volume":"24","author":"W Liu","year":"2025","unstructured":"Liu W, Niu J, Huo Y, Zhang L, Han L, Zhang N, Yang M. Role of circular RNAs in cancer therapy resistance. Mol Cancer. 2025;24:55.","journal-title":"Mol Cancer"},{"key":"2447_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-025-02261-6","volume":"24","author":"X Song","year":"2025","unstructured":"Song X, Wei Z, Zhang C, Han D, Liu J, Song Y, Xie X, Shao D, Zhao M, Chao F, et al. CircAKT3 promotes prostate cancer proliferation and metastasis by enhancing the binding of RPS27A and RPL11. Mol Cancer. 2025;24:53.","journal-title":"Mol Cancer"},{"key":"2447_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101077","volume":"74","author":"F Wang","year":"2024","unstructured":"Wang F, Yu X, Qian J, Cao Y, Dong S, Zhan S, et al. A novel SIK2 inhibitor SIC-19 exhibits synthetic lethality with PARP inhibitors in ovarian cancer. Drug Resist Updat. 2024;74:101077.","journal-title":"Drug Resist Updat"},{"key":"2447_CR31","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/s41416-024-02612-y","volume":"130","author":"LQ Deng","year":"2024","unstructured":"Deng LQ, Shi CJ, Zhou ST, Zeng WQ, Xian YF, Wang YY, et al. EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p\/CTNND1 regulatory axis. Br J Cancer. 2024;130:1517\u201328.","journal-title":"Br J Cancer"},{"key":"2447_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-023-01806-x","volume":"22","author":"R Song","year":"2023","unstructured":"Song R, Guo P, Ren X, Zhou L, Li P, Rahman NA, Wolczynski S, Li X, Zhang Y, Liu M, et al. A novel polypeptide CAPG-171aa encoded by circcapg plays a critical role in triple-negative breast cancer. Mol Cancer. 2023;22:104.","journal-title":"Mol Cancer"},{"key":"2447_CR33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02447-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02447-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:35:11Z","timestamp":1759408511000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02447-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2447"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02447-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study contents and research programs were reviewed and approved by the Ethics Committee of the Fudan University Shanghai Cancer Center (FUSCC, Shanghai, China) (No.050432-4-2108*). The animal experimental protocol was approved by the Institutional Animal Care and Use Committee of the Shanghai Veterinary Research Institute (Approval No. FUSCC-IACUC-2024293).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}